Logo image of ERES

EAST RESOURCES ACQUISITION-A (ERES) Stock Fundamental Analysis

NASDAQ:ERES - Nasdaq - US2746811056 - Common Stock - Currency: USD

10.85  +0.82 (+8.18%)

After market: 13.43 +2.58 (+23.78%)

Fundamental Rating

1

Overall ERES gets a fundamental rating of 1 out of 10. We evaluated ERES against 0 industry peers in the Unkown industry. While ERES seems to be doing ok healthwise, there are quite some concerns on its profitability. ERES has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ERES has reported negative net income.
ERES had a negative operating cash flow in the past year.
ERES Yearly Net Income VS EBIT VS OCF VS FCFERES Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 0 5M -5M 10M -10M 15M

1.2 Ratios

ERES has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ERES Yearly ROA, ROE, ROICERES Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 0 5 -5 -10

1.3 Margins

ERES does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ERES Yearly Profit, Operating, Gross MarginsERES Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022

More info and screens

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, ERES has less shares outstanding
ERES has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ERES Yearly Shares OutstandingERES Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 10M 20M 30M 40M
ERES Yearly Total Debt VS Total AssetsERES Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 100M 200M 300M

2.2 Solvency

ERES has an Altman-Z score of 0.78. This is a bad value and indicates that ERES is not financially healthy and even has some risk of bankruptcy.
ERES has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.78
ROIC/WACCN/A
WACCN/A
ERES Yearly LT Debt VS Equity VS FCFERES Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 0 100M 200M 300M

2.3 Liquidity

ERES has a Current Ratio of 0.01. This is a bad value and indicates that ERES is not financially healthy enough and could expect problems in meeting its short term obligations.
A Quick Ratio of 0.01 indicates that ERES may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.01
Quick Ratio 0.01
ERES Yearly Current Assets VS Current LiabilitesERES Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 5M 10M 15M

More info and screens

0

3. Growth

3.1 Past

ERES shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -229.15%.
EPS 1Y (TTM)-229.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-104.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ERES Yearly Revenue VS EstimatesERES Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022
ERES Yearly EPS VS EstimatesERES Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ERES reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ERES Price Earnings VS Forward Price EarningsERES Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ERES Per share dataERES EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6 0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ERES!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EAST RESOURCES ACQUISITION-A

NASDAQ:ERES (7/3/2023, 7:30:10 PM)

After market: 13.43 +2.58 (+23.78%)

10.85

+0.82 (+8.18%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners5.75%
Inst Owner Change-59.89%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap124.57M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 12.69
P/tB 12.69
EV/EBITDA N/A
EPS(TTM)-0.43
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.25
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS0
BVpS0.86
TBVpS0.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.01
Quick Ratio 0.01
Altman-Z 0.78
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-229.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-104.67%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-787.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-110.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-110.44%
OCF growth 3YN/A
OCF growth 5YN/A